Know Cancer

or
forgot password

HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia


Phase 3
7 Years
60 Years
Open (Enrolling)
Both
Acute Myeloid Leukemia

Thank you

Trial Information

HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia


Inclusion Criteria:



1. Having signed informed consent

2. Diagnosis was based on the French-American-British (FAB) and WHO criteria.

3. Age ≥ 7 years old

4. Age ＜ 60 years old

Exclusion Criteria:

1.Patients with a blast crisis of chronic myeloid leukemia or acute promyelocytic leukemia

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

complete remission

Outcome Time Frame:

one year

Safety Issue:

Yes

Principal Investigator

huisheng ai, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

The Affiliated Hospital of the Chinese Academy of Military Medical Science

Authority:

China: Ethics Committee

Study ID:

MST-AML-307PLAH-ASH

NCT ID:

NCT01484171

Start Date:

August 2011

Completion Date:

December 2013

Related Keywords:

  • Acute Myeloid Leukemia
  • Acute Myeloid Leukemia
  • idarubicin
  • Microtransplantation
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid

Name

Location